Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles as ALK5 inhibitors

References

• Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013;13:788–99.
   PubMed Web of Science ®Google Scholar
• Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375–82.
   PubMed Web of Science ®Google Scholar
• Ivanovic V, Todorovic-Rakovic N, Demajo M, et al. Elevated plasma levels of transforming growth factor- β1 (TGF- β1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 2003;39:454–61.
   PubMed Web of Science ®Google Scholar
• Dave H, Shah M, Trivedi S, Shukla S. Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int J Biol Markers 2012;27:53–9.
   PubMed Web of Science ®Google Scholar
• Eder IE, Stenzl A, Hobisch A, et al. Transforming growth factors-β1 and β2 in serum and urine from patients with bladder carcinoma. J Urol 1996;156:953–7.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001;92:2985–92.
   PubMed Web of Science ®Google Scholar
• Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182–7.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta1 (TGF-β1) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856–64.
   PubMed Web of Science ®Google Scholar
• Krasagakis K, Thölke D, Farthmann B, et al. Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma. Br J Cancer 1998;77:1492–4.
   PubMed Web of Science ®Google Scholar
• Zhao J, Liang Y, Yin Q, et al. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma. Braz J Med Biol Res 2016;49:e5485.
   Web of Science ®Google Scholar
• Lin TH, Shao YY, Chan SY, et al. High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib. Clin Cancer Res 2015;21:3678–84.
   PubMed Web of Science ®Google Scholar
• Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506–20.
   PubMed Web of Science ®Google Scholar
• Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015;9:4479–99.
   PubMed Web of Science ®Google Scholar
• Faivre S, Santoro A, Kelley RK, et al. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int 2019;39:1468–77.
   PubMed Web of Science ®Google Scholar
• Jin CH, Krishnaiah M, Sreenu D, et al. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent. J Med Chem 2014;57:4213–38.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massague J. Transforming growth factor-beta signaling in immunity and cancer. Immunity 2019;50:924–40.
   PubMed Web of Science ®Google Scholar
• Patel HM, Sing B, Bhardwaj V, et al. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5). Eur J Med Chem 2015;93:599–613.
   PubMed Web of Science ®Google Scholar
• Reznickova E, Tenora L, Pospisilova P, et al. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles. Eur J Med Chem 2017;127:632–42.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Jung SM, Park SH, et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Mol Med 2013;5:1720–39.
   PubMed Web of Science ®Google Scholar
• Son JY, Park SY, Kim SJ, et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther 2014;13:1704–16.
   PubMed Web of Science ®Google Scholar
• Naka K, Ishihara K, Jomen Y, et al. Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells. Cancer Sci 2016;107:140–8.
   PubMed Web of Science ®Google Scholar
• Park SA, Kim MJ, Park SY, et al. EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling. Cell Mol Life Sci 2015;72:2023–39.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Park SA, Kim CH, et al. TGF-β type I receptor kinase inhibitor EW-7197 suppresses cholestatic liver fibrosis by inhibiting HIF1α-induced epithelial mesenchymal transition. Cell Physiol Biochem 2016;38:571–88.
   PubMedGoogle Scholar
• Jun EJ, Park JH, Tsauo J, et al. EW-7197, an activin-like kinase 5 inhibitor, suppresses granulation tissue after stent placement in rat esophagus. Gastrointest Endosc 2017;86:219–28.
   PubMed Web of Science ®Google Scholar
• Han K, Park JH, Yang SG, et al. EW-7197 eluting nano-fiber covered self-expandable metallic stent to prevent granulation tissue formation in a canine urethral model. PLoS One 2018;13:e0192430.
   PubMed Web of Science ®Google Scholar
• Tsauo J, Song HY, Choi EY, et al. EW-7197, an oral transforming growth factor β type I receptor kinase inhibitor, for preventing peritoneal adhesion formation in a rat model. Surgery 2018;164:1100–8.
   PubMed Web of Science ®Google Scholar
• Sybyl-X 2.1.1. SYBYL molecular modeling software. St. Louis (MO): Tripos Inc.; 2013.
   Google Scholar
• Sawyer JS, Beight DW, Britt KS, et al. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorg Med Chem Lett 2004;14:3581–4.
   PubMed Web of Science ®Google Scholar
• Gaster LM, Hadley MS, Harling JD, et al. Pyridinylimidazoles. Patent WO 01/62756 A1; 2001.
   Google Scholar
• Powers JC, Boduszek B, Oleksyszyn J, Basic alpha-aminoalkylphosphonate derivatives. Patent US 5,686,419 A; 1997.
   Google Scholar
• Kelly SM, Liquid crystals. Patent US 5,204,018 A; 1993.
   Google Scholar
• Diulgheroff N, Pirkes M, Pontiroli A, Villa M. Processes for preparing intermediates of pemetrexed. Patent WO 2008/021385 A2; 2008.
   Google Scholar
• Kim D-K, Jung SH, Lee HS, Dewang PM. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Eur J Med Chem 2009;44:568–76.
   PubMed Web of Science ®Google Scholar
• Pasternak A, Dejesus RK, Zhu Y, et al. Inhibitors of the renal outer medullary potassium channel. Patent WO 2012/058134 A1; 2012.
   Google Scholar
• Fleury-Brégeot N, Oehlrich D, Rombouts F, Molander GA. Suzuki-Miyaura cross-coupling of potassium dioxolanylethyltrifluoroborate and aryl/heteroaryl chlorides. Org Lett 2013;15:1536–9.
   PubMed Web of Science ®Google Scholar
• Byfield SD, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004;65:744–52.
   PubMed Web of Science ®Google Scholar
• Gellibert F, Woolven J, Fouchet MH, et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem 2004;47:4494–506.
   PubMed Web of Science ®Google Scholar
• Kim D-K, Jang Y, Lee HS, et al. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors. J Med Chem 2007;50:3143–7.
   PubMed Web of Science ®Google Scholar
• Eyers PA, Craxton M, Morrice N, et al. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 1998;5:321–8.
   PubMedGoogle Scholar
• Spitzer R, Jain AN. Surflex-Dock: Docking benchmarks and real-world application. J Comput Aided Mol Des 2012;26:687–99.
   PubMed Web of Science ®Google Scholar